Our Vision
We seek to improve the lives of patients with autoimmune disease. Through immuno-autonomics, we understand how stress drives these diseases to excess.
What We Do
Inmedix has discovered and is working with partners to commercialize a novel class of diagnostics, therapeutics and cloud-based analytic strategies.
Our approach uses next-gen diagnostics and cloud-based data analytics on autonomic nervous system (ANS) control of stress responses within the brain. In the setting of an autoimmune disease, ANS stress can significantly intensify an autoimmune disease. We call it Immuno-autonomics. We seek to understand and block this process to allow current autoimmune disease therapies to work much better.
More About Inmedix View Our Team
Our story
Inmedix Timeline
2001
2003
2004
2006
2007
2008
2013
2014
2015
2016
2017
2018
2020
2021
2022
2023
ANS stress, FM and RA activity linked at EULAR meeting in Stockholm.
HRV linked with FM severity and effective TNFi treatment of RA at BSR meeting in Edinburgh.
First successful RCT of dopamine agonists to treat FM at ACR meeting in San Antonio.
Inmedix founded as a patent holding company.
Sale of dopamine agonist – FM international Inmedix patents.
First predictive ECG biomarker (HRV) for TNFi therapy.
Inmedix converts from a patent holding to a diagnostic/therapeutic company.
Inmedix builds commercial team.
First successful pilot study to enhance TNFi with ANS optimization.
Inmedix UK Ltd subsidiary established, converts to Inmedix Inc and flied first ANS Therapeutics patent.
Research prototype created for clinical studies
Expanded research in COVID and long COVID
Created executive team from diagnostic industry experts
Anticipated FDA 510(k) submission
